Board of Directors

  • Sarah Howell, Ph.D., Chief Executive Officer

    Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.

    Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

    Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

  • Andrew J M Richards, Ph.D., CBE (Chairman)

    Andy is an established biotechnology entrepreneur and investor with broad experience from the UK biotechnology sector in research, drug development, commercial deals and scaling up companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, and a director of Silence Therapeutics plc, Sensiia Ltd, and Ieso Digital Health Ltd. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial arm of Cancer Research UK).

    Andy is a Cambridge graduate with a Ph.D. in enzyme chemistry and was a founder of Chiroscience in 1992 and an Executive Director through to the Celltech deal in 1999. Andy has a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd.

  • Sam Fazeli, Ph.D., Non-Executive Director

    Sam has served as a member of our Board of Directors since September 2017 and he brings over nineteen years of experience of conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.

    Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys. He received a first degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.

  • Ian Freelance

    Ian is currently a board member of Arecor, Regentis, Essential Medical, Isobionics, nutriLeads, BioProcess Control and NovoPolymers.

    Ian has a broad experience within the life science industry covering biotech, medtech and nutrition. He has been with DSM Venturing since 2008, investing in Europe, the US and Israel. He is today more focused upon life science and material science investments within Europe and Israel. Ian has over 23 years’ experience in life science and technology driven companies, 16 years of which being within the pharmaceutical industry, addressing both innovative biotech companies as well as global pharma companies.

  • Andrew Lane, MA

    Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University. He is a founding Director of Unilever Ventures which focuses on investments in Home and Personal Care Technology.

    He has been involved as a Director in the set-up and development of three other life science businesses (BAC BV, Pharmakodex Ltd, and Insense Ltd).

  • Thomas Reese Saylor, MBA

    Tom has a background in management, strategy development, deal negotiation and fundraising for entrepreneurial biopharma companies. He was the CEO of Sirus Pharmaceuticals Limited, a company developing drugs based upon advanced delivery technologies, which he built through internal development and acquisition and then successfully sold to Arakis Limited in 2004. He was also a Chairman and founder of Lotus Healthcare Corporation, an Asian-based fully integrated pharmaceutical company producing and marketing analgesics, cardiovascular and GI products in 35 cities of China.

    He was also CEO of Cell Systems Limited, a company focusing on medical applications of cryo-preservation and algal biotechnology, and Executive Vice President of a multibillion dollar trade and finance company based in New York. As a ministerial appointment in the US Government, Tom was a principal trade negotiator for the United States during the Tokyo Round. Tom represents the United Kingdom as a member of the EuropaBio Board of Directors. Tom holds an MBA from Harvard University, doctoral studies in molecular biology at the Max Planck Institute for Psychiatry in Munich and a degree in molecular biology from the Georgia Institute of Technology.

  • Alan E Smith, Ph.D., FRS, CBE

    Alan is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the vice president and scientific director of Integrated Genetics, a MA start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of: The Cancer Research Institute in Cambridge UK; Pharnext – a start-up genomics company in Paris, France; and ImmuneXcite – a start-up immunology company, in Lexington MA. He is on the Board of Directors of Advantagene – a start-up gene therapy company in Newton MA.

    He is chairman of the Board of Cambridge in America, the representative body of the University and Colleges of Cambridge in North America. Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ’s College.